Meet the speakers for the HUPO ReCONNECT 2021. In order to learn more about each individual speaker, please click on the photos below.
Isabell Bludau is a postdoctoral fellow in the lab of Prof. Matthias Mann at the Max Planck Institute of Biochemistry near Munich. During her Ph.D. with Prof. Ruedi Aebersold at the Institute of Molecular Systems Biology, ETH Zurich, Isabell developed computational methods for analyzing large-scale proteomics data. She specifically focused on the detection and quantification of protein complexes. Recently, Isabell’s work focuses on the inference of different proteoforms and their crosstalk. Isabell’s Ph.D. thesis was awarded with the ETH silver medal and her postdoctoral research is supported by a Postdoc. Mobility fellowship of the Swiss National Science Foundation.
In 1994, Marc Wilkins developed the concept of the proteome and coined the term. He has since published >220 peer-reviewed research papers, review papers, and book chapters in the fields of proteomics, genomics/transcriptomics, and systems biology. In proteomics, he has a focus on the functional analysis and regulation of protein methylation.
In industry, Wilkins has co-founded two biotechnology companies. Proteome Systems Ltd, established in 1999, developed proteomics technology and a platform for rapid point-of-care diagnostic testing. Regeneus Pty Ltd, established in 2007, has pioneered the clinical use of adult stem cells to treat a range of musculoskeletal disorders.
Wilkins has been elected to the council of HUPO four times, is a current council member, and was program chair of HUPO2010 (Sydney) and a co-organizer of HUPO2019 (Adelaide). He serves on the management committee of the Australian Proteomics Society and is a co-organizer of its annual conference.
Dr. Yves Vandenbrouck has been working at the BioHealth Department (CEA, University of Grenoble, FR) as PI, in close collaboration with both a proteomics infrastructure, data scientists, and biologists/clinicians. His research interests focus on the design of bioinformatics tools and strategies to leverage the ever-increasing wealth and diversity of “omics” data for biomarkers discovery and the elucidation of biological processes underlying human diseases (orcid: 0000-0002-1292-373X). For many years, Yves has been active in the HUPO community by contributing to the Human Proteome Project and as a co-founder of the “Bioinformatics Hub”. He is also involved in community efforts such as the European Elixir proteomics initiative, which aims at disseminating proteomics data analysis pipelines, and the “Galaxy for Mass Spectrometry” workgroup. During this session, Yves will introduce ProteoRE, a Galaxy-based instance for the interpretation of proteomics data for biomedical research.
David Tabb began work in proteome informatics in 1996, when he began Ph.D. training with the John Yates lab. Twenty-five years later, he has gained experience in challenges ranging from proteomic database search to identification of phospholipids. After moving to South Africa in 2015 and to France in 2021, he has found great joy in training other scientists, ranging from B.Sc. Honours students to post-doctoral researchers. Many of his training lectures can be found through his blog site: https://pickingupthetabb.wordpress.com/
Brian Searle is an Assistant Professor at the Ohio State University Medical Center in the Department of Biomedical Informatics and a member of the Pelotonia Institute for Immuno-Oncology. Brian received his chemistry BA at Reed College in 2001. In 2004, he co-founded Proteome Software with Mark Turner and Dr. Ashley McCormack to produce and distribute cutting-edge data analysis software for proteomicists. In 2014, he returned to academia to earn his Ph.D. with Dr. Michael MacCoss at the University of Washington, where he developed methods to detect and quantify proteins and phosphosites using mass spectrometry. His lab spans the intersection of proteomics, mass spectrometry, bioinformatics, and technology development to study human genetic variation in the backdrop of cancer.
Lindsay has over a decade of experience in developing mass spectrometry proteomics methods for studying human disease. She has trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania. Her focus is on developing techniques for quantitative proteomics. She’s interested in the challenges associated with scaling-up quantitative proteomics experiments. Lately, she’s been working on expanding these techniques to target dynamic systems including protein turnover, epigenetics, and protein interactions.
Michael MacCoss has been working with mass spectrometry instrumentation since 1994 when he was an undergraduate in a stable isotope geochemistry lab at the University of Vermont. He became interested in biomedical applications working in Dr. Patrick Griffin’s protein mass spectrometry lab at Merck Research Laboratories during two summer internships in 1995 and 1996. In 2001, he completed a Ph.D. in Analytical Chemistry with Professor Dwight Matthews in the development of stable isotope and mass spectrometry methodologies for the measurement of human amino acid and protein metabolism. After completing his degree, Dr. MacCoss moved to The Scripps Research Institute to work with the proteomics pioneer John R. Yates III as a postdoctoral fellow. During his postdoctoral training, Dr. MacCoss worked on methodology and software for many areas of proteomics, ranging from the improved characterization of post-translational modifications and the quantitative analysis of complex protein mixtures. Dr. MacCoss moved to the University of Washington in 2004 as an Assistant Professor of Genome Sciences and was promoted to Professor in 2014. At the University of Washington, his lab has focused on the development and application of mass spectrometry-based technologies for the high throughput characterization of complex protein mixtures. Realizing that software was a major limitation in proteomics, Dr. MacCoss has established a major software engineering effort within his group at the University of Washington. Their laboratory’s software is noted for its robustness, versatility, and user-friendliness. Dr. MacCoss and his team continually work to improve their tools, provide documentation, and a community around their software. In 2007 he was the recipient of a Presidential Award for Scientists and Engineers (PECASE). He was selected to receive the Biemann Medal from the American Society for Mass Spectrometry and the 2016 HUPO Award for Discovery in Proteomics Sciences. The MacCoss lab's research has been at the intersection of biochemistry, instrumentation, engineering, computer science, and statistics.
Mathieu Lavallée-Adam is an Assistant Professor at the University of Ottawa in the Department of Biochemistry, Microbiology, and Immunology and at the Ottawa Institute of Systems Biology. He obtained a B.Sc. in Computer Science and a Ph.D. in Computer Science from McGill University. He then performed his postdoctoral research at Scripps Research. His research focuses on the development of statistical and machine learning algorithms for the analysis of mass spectrometry-based proteomics data and protein-protein interaction networks. He also designs computational methods mining proteomics datasets for biological information through their integration with genomics data. Dr. Lavallée-Adam is a recipient of the John Charles Polanyi Prize in Chemistry, recognizing the impact of his algorithms on the proteomics community. One of his publications was also recognized as the Highlight of the Year by an early career researcher at the HUPO World Congress. He is also Co-Chair of the HUPO Early Career Researcher Initiative.
Currently, Maike is working at Medicines Discovery Catapult on a collaborative study with LifeArc focused on applying mass spectrometry-based proteomics in the field of drug discovery. She is finishing her Ph.D. in chemistry at the Heinrich Heine University Düsseldorf with Prof Kai Stühler. Previous research focused on lncRNA-based perturbations of protein signatures in brain tumours, secretome analysis in cancer cell lines, tumour tissue proteomics and phospho-proteomics.
Since 2017, Maike has been working with the Young Proteomics Investigators Club (YPIC) the early career researcher group of EuPA, and was elected as their president in 2020.
Ed Huttlin is an Instructor in the Department of Cell Biology at Harvard Medical School, where he oversees the BioPlex project– a longstanding effort to profile protein-protein interactions in human cells via affinity-purification mass spectrometry (bioplex.hms.harvard.edu)– as co-Principal Investigator along with Professors Steve Gygi and Wade Harper. In this capacity, Ed is responsible for all aspects of quality control, data analysis, and dissemination.
Although his recent work is heavily computational, Ed earned his Ph.D. in Biochemistry at the University of Wisconsin, Madison, working in the lab of Professor Michael Sussman on quantitative proteomics applications of in vivo 15N metabolic labeling in organisms ranging from Arabidopsis to mice. He then joined the lab of Steve Gygi at Harvard where he has participated in the development of isobaric labeling technology and led an effort to profile protein expression and phosphorylation across nine mouse tissues prior to assuming responsibility for the BioPlex project.
Ruth Huttenhain is an Assistant Professor at the University of California, San Francisco (UCSF) in the Department of Cellular and Molecular Pharmacology. She obtained a Pharmacy degree from the University of Bonn and a Ph.D. from ETH Zurich, Switzerland, where she developed high-throughput, large-scale targeted mass spectrometric approaches. During her postdoc at UCSF, Ruth extended her expertise in quantitative mass spectrometry to study the dynamics of protein interaction networks. She pioneered a proximity labeling-mass spectrometry approach that simultaneously captures the precise temporal remodeling and spatial organization of proximal protein networks. The research of Ruth’s research group at UCSF focuses on characterizing protein interaction and signaling networks with the spatiotemporal resolution to understand the biology underlying the development of psychiatric disorders and the sensing and transmission of pain. Ruth is Co-Chair of the HUPO Early Career Researcher (ECR) Initiative.
"Andreas Hober graduated from KTH Royal Institute of Technology in 2017 with a Master of Science in Engineering and was awarded the Honnörsstipendium (Best Graduate of the Year), within the Biotechnology program. He is currently enrolled as a Ph.D. student in the group of Targeted Proteomics at KTH Royal Institute of Technology, headed by Prof. Mathias Uhlén
Andreas Hober’s research is centered around the development of targeted proteomics methods for more sensitive assays. His focus is on developing precise quantification for clinically relevant protein targets in human blood plasma to be used for precision medicine applications. Within this area, an assay for monitoring the levels of apolipoproteins in clinical cohorts has already been implemented and a SISCAPA-based method for SARS-CoV-2 diagnostics has been developed. The current goal is to continue this path and develop assays for monitoring low abundant FDA approved protein targets by using affinity reagents."
Tiannan received training in clinical medicine (1999-2006) in Tongji Medical College, Huazhong University of Science and Technology, and learned biology (2001-2005) at Wuhan University before he moved to Singapore for Ph.D. training in cancer proteomics (2008-2012) in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr.Oi Lian Kon in National Cancer Centre Singapore. In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. Tiannan moved to Sydney as the Scientific Director of ProCan, group leader of Cancer Proteome, Children’s Medical Research Institute, conjoint senior lecturer in The University of Sydney Medical School, in March 2017. Tiannan joined the Westlake Institute for Advanced Studies, Westlake University in August 2017 as a Tenure Track Assistant Professor. More in www.guomics.com.
Dr. Jennifer Geddes-McAlister completed her Ph.D. from the University of British Columbia (Canada) under the supervision of Dr. Jim Kronstad focusing on the impact of signal transduction cascades in the human fungal pathogen, Cryptococcus neoformans. She reported the first biomarkers of cryptococcal infection and discovered a novel drug-repurposing strategy to treat cryptococcosis. She then went on to pursue a post-doctoral fellowship funded through the Alexander von Humboldt Foundation at the Max Planck Institute of Biochemistry (Germany) under the guidance of Prof. Dr. Matthias Mann, a world-renowned leader in mass spectrometry-based proteomics. In July 2018, Dr. Geddes-McAlister started her own research group at the University of Guelph (Canada) where her research team explores the intricate relationships between pathogen and host during infection from a systems biology perspective with both medical and agricultural relevance. She currently manages a lab of 25 trainees with diverse funding and industry partnerships to advance our knowledge of infection and propose new treatment strategies.
Cheng Chang received his B.E. in Electronic Engineering from Hunan University, China, in 2010 and received his Ph.D. in Bioinformatics from Beijing Proteome Research Center, China, in 2015. Currently, he is an associate research fellow in the Department of Biomedical Big Data, Beijing Proteome Research Center, and National Center for Protein Sciences, Beijing. His major research interests include proteomics, bioinformatics, and precision medicine.
Dr. Lundberg is a Professor in Cell Biology Proteomics at KTH Royal Institute of Technology, Sweden, and Director of the Cell Atlas, of the Human Protein Atlas program. For this work she was recently top 10 under 40; future leaders in biopharma. Dr. Lundberg recently spent three sabbatical years as visiting Associate Professor at Stanford School of Medicine and the Chan-Zuckerberg Biohub. In the interface between bioimaging, proteomics, and artificial intelligence her research aims to define the spatiotemporal proteome organization of human cells, to understand how variations in protein expression patterns contribute to cellular function and disease.
Kun-Hsing "Kun" Yu, MD, Ph.D. is an Assistant Professor in the Department of Biomedical Informatics at Harvard Medical School. He integrates cancer patients' multi-omics (genomics, epigenomics, transcriptomics, and proteomics) profiles with quantitative histopathology patterns to predict their clinical phenotypes. He developed the first fully automated algorithm to extract thousands of features from whole-slide histopathology images, discovered the molecular mechanisms underpinning the microscopic phenotypes of tumor cells, and successfully identified previously unknown cellular morphologies associated with patient prognosis. Dr. Yu's research interests include quantitative pathology, machine learning, and pathology-multiomics data integration.
Chia-Jung Yu is a professor at the Department of Cell and Molecular Biology, Chang Gung University in Taiwan. Yu applies the integrative omics approach in clinical proteomics and molecular cell study. She works on the discovery and functional characterization of biomarkers in lung cancer progression and drug resistance. Her recent studies focus on the development of therapeutic targets and liquid biopsy to benefit lung cancer patients. Yu also investigates the function of Golgi-associated proteins for specific cellular functions in cancer cells. Yu is the director of the instrumentation center at Chang Gung University since 2016. She is active in the Taiwan Proteomics Society (TPS) and The Taiwan Society for Biochemistry and Molecular Biology (TSBMB). Her recent publication can be found in Clinical Cancer Research, Molecular & Cellular Proteomics, Journal of Proteome Research, Journal of Cell Science, and The FASEB Journal.
Professor Catherine C.L. Wong is the Director of Center for Precision Medicine Multi-omics Research (CPMMR), Associate Professor with Tenure at School of Basic Medical Sciences, Peking University Health Science Center, Principal Investigator at Peking University-Tsinghua University Center for Life Sciences (CLS), and Honorary Professor at the University of Manchester. She has been dedicating to the development of cutting-edge mass spectrometry-based proteomics technologies and their applications in basic biological and biomedical research. Moreover, to discover authentic disease biomarkers and to unveil disease mechanisms based on a large clinical cohort were also her main pursuing. She used multi-omics technologies, combined with biotechnology, chemical biology, neural networks, and other interdisciplinary technologies for functional verification, mechanism analysis, as well as the clinical application of IVD. At present, multiple pipelines including tumors and mental diseases are in development and transformation. Professor Wong has published over 80 articles in the journals such as Cell, Science, Nature Methods, Nature Communications and so on.
Bernd Wollscheid is a Professor at the Institute of Translational Medicine at the Department of Health Sciences and Technology at the Federal Swiss Institute of Technology / ETH Zurich. Prof. Wollscheid is a chemical biologist who is spearheading a research team that develops, applies, and translates next-generation molecular health technologies to gain new insights into how molecular nanoscale organization influences biological function in health and disease. By using an array of technologies at the interface of Biology, Chemistry, Medicine, and Bioinformatics the Wollscheid laboratory strives to functionally understand the cellular surfaceome as a complex information/signaling gateway connecting the intracellular to the extracellular interactome. Wollscheidlab.org
Dr. Van Eyk is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center, and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. Most recently she has become the co-director of the Cedars Sinai Precision Health, focused on in-hospital and population individualization of health care. Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused the developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data-independent acquisition. Her laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.
"Dr. Henry Rodriguez is the Founding Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Rodriguez is also a member of NCI’s Senior Leadership. A cell and molecular biologist with a background in business, Dr. Rodriguez’s biomedical research has focused on mechanisms of cancer in basic and clinical science, and the development of measurement science, standards, and technology.
Dr. Rodriguez earned his A.A. in biology from Miami Dade College, B.S. in biology/chemistry and M.S. in biology from Florida International University, Ph.D. in cell and molecular biology from Boston University, and M.B.A. in finance and management from Johns Hopkins University Carey Business School. Fellowships were conducted at the Scripps Research Institute and City of Hope Comprehensive Cancer Center. Dr. Rodriguez has authored more than 147 original research papers, including co-editing a book on oxidative stress and aging."
Rob Rivers, Ph.D. is a program director in the Office of Minority Health Research Coordination (OMHRC) at the National Institute of Diabetes, Digestive and Kidney Diseases, one of the Institutes that comprise the United States National Institutes of Health. He leads programs focused on increasing the biomedical research workforce's diversity and expanding support in health disparities-related research. His doctoral research focused on studying intrinsically disordered proteins and their propensity to aggregate and their implications in disease. He earned a Ph.D. degree in Chemistry from the University of Cambridge and a B.S. degree in Chemistry from Kentucky State University.
Juri Rappsilber studied chemistry at the Technische Universität Berlin (Germany), Strathclyde University, Glasgow (UK), and with Tom Rapoport, Harvard Medical School, Boston (USA). In 2001, he earned his Ph.D. jointly from EMBL Heidelberg and the Johann Wolfgang Goethe University, Frankfurt (Germany) working in the laboratory of Matthias Mann on the mass spectrometric analysis of protein complexes. He completed a postdoctoral fellowship at the University of Southern Denmark, Odense before starting his independent career at IFOM, Milan (Italy) in 2003. In 2006, Juri joined the Wellcome Centre for Cell Biology, University of Edinburgh, twice obtaining Senior Research Fellowships of the Wellcome Trust and since 2010 being Professor of Proteomics. Since 2011, he is Professor of Bioanalytics at the Technische Universität Berlin. Juri combines organic chemistry and computational sciences with advanced mass spectrometry, to expand the frontiers of our understanding of the structural and mechanistic basis of how cells work.
Dr. Nita-Lazar received her Ph.D. in biochemistry in 2003 from the University of Basel for studies performed at the Friedrich Miescher Institute for Biomedical Research, where she studied protein glycosylation using mass spectrometry. After postdoctoral training at Stony Brook University and Massachusetts Institute of Technology, where she continued to investigate post-translational protein modifications and their influence on cell signaling, she joined the Program in Systems Immunology and Infectious Disease Research, now the Laboratory of Immune System Biology, in April 2009 as an Investigator and Chief of the Cellular Networks Proteomics Unit. In 2018 she became a tenured Senior Investigator and Chief of the Functional Cellular Networks Section.
Ed Nice is currently a Professor at Monash University where he is Head of Clinical Biomarker Discovery and Validation (Department of Biochemistry and Molecular Biology) and a scientific advisor to the Monash Antibody Technologies Facility (MATF), for which he was director from 2009 - 2013. He also holds a Visiting Professorship at Sichuan University/West China Hospital and an Adjunct Professor position at Macquarie University, Sydney, Australia. His long-term research interests have been in protein and peptide micropurification, biomarker discovery and validation, SPR analysis, high throughput monoclonal antibody production and validation, and clinical biomarker assay development, with a strong translational focus on colorectal cancer, especially the field of faecal proteomics for colorectal cancer detection and surveillance.
Professor Matthias Mann obtained his Ph.D. in chemical engineering at Yale, contributing to the Nobel Prize for his supervisor John Fenn for electrospray ionization. He is a Research Director of the Proteomics and Signal Transduction Department at the Max-Planck Institute of Biochemistry (Germany) and the Proteomics Program at Novo Nordisk Foundation Center for Protein Research (Denmark). He is the recipient of several prestigious honors and is the highest cited German researcher with an h-index 240 and over 275,000 citations (Google scholar). He has pioneered advances in sample preparation, chromatography, mass spectrometry, and computer algorithms to make proteomics applicable to molecular biology. His team has made landmark contributions in signal transduction, biomarker discovery, and metabolic diseases and are continually developing novel proteomic methods to understand human diseases better, more recently, at single-cell resolution. His vision is to bring proteomics expertise into clinics for guiding diagnostics and prognostic decisions.
Professor Ho Jeong KWON graduated from Seoul National University (BSc, Korea) and did MS and Ph.D. from the University of Tokyo (Japan) and postdoctoral training at Harvard (USA). He returned to Korea in 1999 and was promoted to full professor in 2008 at the department of biotechnology, Yonsei University. He has been director of the chemical genomics Global Research Laboratory (GRL) program and serving as an adjunct professor at, College of Medicine, Yonsei University and Lund University (Sweden), and SAC member of Institut Pasteur Korea. He has been serving as the president of AOHUPO (20-present) and served as a council member of HUPO (05-08, 15-17, 19-present), the president of KHUPO (10-11), and the president of the Korean Society for Vascular Biology and Medicine (18-20). He has published over 220 papers in reputed journals (Google scholar citation; Total citation: 17,534, h-index: 50) and has been serving as editor-in-chief of Proteome Science and editor of repute journals. He has also filed over 50 patents and received many awards including the Doheon Biochemistry Award (KSBMB, 2020), Sura Academy Award (KMB, 2006), and Outstanding Research Professor Awards of Yonsei University (2011, 2013, 2016, 2017, 2018), Outstanding Teaching Award by Yonsei University (2008, 2013, 2020). His research interests focus on the discovery of bioactive small molecules, target identification and validation, integration of omics technologies toward innovations in drug discovery and translational research.
Bernhard is a chemist by training and holds a Ph.D. in biochemistry from Oxford University. Before joining the Technical University of Munich (TUM) as a Full Professor of Proteomics, he was Vice President at Cellzome (now GSK). At TUM, he serves as the Director of the Bavarian Biomolecular Mass Spectrometry Center and Vice Dean of Information Management of the School of Life Sciences. His research follows three major themes: i) mapping proteomes, ii) understanding how drugs work, and iii) building ProteomeTools. The work of his team has been awarded the Discovery in Proteomic Sciences Award of HUPO and an ERC Advanced Grant. Bernhard is a Carl von Linde Senior Fellow of the TUM Institute for Advanced Study and was recently elected to the German National Academy of Science. Bernhard has co-founded two start-up companies that operate in the areas of proteomics and artificial intelligence.
Gary Kruppa currently serves as the vice president for proteomics at Bruker Datlonics Inc. He manages a growing global team of applications and applications development scientists, focused on customer support and developing new proteomics applications. Dr. Kruppa earned his Ph. D. in chemical physics at CalTech. Dr. Kruppa has been working with Bruker since 1991 eventually serving as Vice President for FTMS. From 2001 to 2004 Dr. Kruppa ran his own research lab at Sandia National Labs, where he and his team developed novel methods and reagents for chemical crosslinking of proteins. From 2004 to 2014 he served as vice president for business development at Bruker. From 2014 to 2016 Dr. Kruppa served as CEO of MRM Proteomics Inc. Dr. Kruppa returned to Bruker in 2016 to serve as vice president for proteomics, where he helped launch the revolutionary timsTOF Pro QTOF mass spectrometer powered by the PASEF method.
Lisa M. Jones is an Associate Professor in the Department of Pharmaceutical Sciences at the University of Maryland. She received postdoctoral training in structural virology at the University of Alabama- Birmingham and in MS-based protein footprinting at Washington University in St. Louis. Dr. Jones’s research interests include the use of the protein footprinting method fast photochemical oxidation of proteins (FPOP) coupled with mass spectrometry for the characterization of the higher-order structure of proteins. In particular, her lab has further developed the FPOP method for in-cell (IC-FPOP) studies for proteome-wide structural biology. Biological applications of IC-FPOP include characterizing protein folding intermediates directly in the cell and drug target (both on and off-targets) determination. The Jones lab has also extended the method for in vivo analysis (IV-FPOP) in C. elegans. This provides the ability to study protein structure in an animal model for human disease.
Dr. Ling Hao is an Assistant Professor of Chemistry at the George Washington University in Washington, D.C. She received her PhD from the University of Wisconsin-Madison, followed by postdoctoral training at the National Institutes of Health. She joined the faculty at GW since 2019, leading a research team and also teaching chemistry courses for both undergraduate and graduate students. She has co-authored 25 publications and served as a reviewer for 15 research journals and a guest editor for the Journal of Visualized Experiments. She received the ORAU Ralph E. Powe Junior Faculty Enhancement Award, GW University Facilitating Fund, and an NIH R01 grant to support her research in developing mass spectrometry-based strategies to study mitochondrial and lysosomal dysfunctions in neurodegenerative diseases. Hao Lab’s research is focused on developing proteomics, metabolomics, and proximity labeling techniques to understand the molecular mechanisms of neurological disorders and discover molecular biomarkers for brain diseases.
Postdoctoral scientist at ACBRI under the supervision of Dr. Jennifer Van Eyk. Working on clinical studies using mass spectrometry for plasma and remote sampling devices. Developing single-cell proteomics approach to better understand cardiac diseases.
Mehdi ("Meh-Di") Bouhaddou is currently a National Cancer Institute postdoctoral fellow at UCSF advised by Nevan Krogan. Using both experimental and computational approaches, Mehdi specializes in integrating large biological datasets to understand how diseases, and potential therapies, can rewire cellular signaling — with applications in cancer and infectious disease.
Ruedi Aebersold is a Swiss and Canadian scientist. He trained at the Biocenter, University of Basel and completed his education at Caltech. He was on the faculties of the Universities of British Columbia and Washington and co-founded, with Lee Hood and Alan Aderem, the Institute for Systems Biology in Seattle, a world first. He was a Professor at ETH Zurich and the University of Zurich from 2004 until 2020. The research focus of the Aebersold group was the proteome. Ruedi has co-founded several companies and holds several public service appointments. He was awarded an honorary doctorate of the University of Lund, Sweden and the work of the group was recognized with numerous prizes and awards. In 2020, Ruedi received the prestigious Marcel Benoist Swiss Science Prize for his pioneering work in the field of systems biology.
1) Accurate quantitation of protein expression and site-specific phosphorylation
PNAS, 96 (12), 6591-6596 1999
2) Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome
Nature Biotech 19 (4), 379-382 2001
3) Quantitative chemical proteomics for identifying candidate drug targets
Anal Chem 75 (9), 2159-2165 2003
4) Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards
Nature Biotech 23 (5), 617-621 2005
5) Synaptic activity prompts γ-secretase–mediated cleavage of EphA4 and dendritic spine formation
J. Cell Biol. 185 (3), 551-564 2009
6) Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology
J. Lipid Res 53 (3), 567-576 2012
7) Circulating miRNA biomarkers for Alzheimer's disease
PLoS One 8(7):e69807 2013
8) Isobaric mass tagging and triple quadrupole mass spectrometry to determine lipid biomarker candidates for Alzheimer's disease
PLoS One 14(12):e0226073 2019
Steve is a Professor of Proteomics at University College Dublin, Ireland. A chemist (Imperial College, London) and Ph.D. biochemist (University of Cambridge) by training, predominantly in human disease. Steve has been active, including roles as a committee member, in the British Society for Proteome Research for which he is currently President, the European Proteomics Association, and is currently past-President of HUPO.
Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high-resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor (TF) binding sites (ChIP-chip now replaced by ChIP-seq), paired-end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes, and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and a high diversity of transcription factor binding occurs both between and within species. He launched the field of personalized medicine by combining different state-of-the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smartwatches and continuous glucose monitoring) for precision health. He is a co-founder of many biotechnology companies, including Personalis, SensOmics, Qbio, January, Protos, Oralome, Mirvie, and Filtricine.
Dr. Juan Antonio Vizcaíno is the Proteomics Team Leader at the European Bioinformatics Institute (EMBL-EBI, Cambridge, UK). His team is responsible for the development of the PRIDE database, the world-leading public repository for mass spectrometry (MS) proteomics data (http://www.ebi.ac.uk/pride), and related tools and resources. In addition, he is coordinating the ProteomeXchange Consortium, aiming to standardize data submission and dissemination in proteomics resources worldwide. Over the years, he has heavily contributed to the development of many proteomics data standard formats (mzIdentML, mzQuantML, mzTab, proBed, proBAM, Universal Spectrum Identifiers) and related software, as part of his contribution to the HUPO Proteomics Standards Initiative (PSI).
He has been the leading author of highly-cited publications in journals such as Nature Biotechnology, Nature Methods, Nucleic Acids Research, Genome Biology, and Molecular and Cellular Proteomics, among others. Overall, he has published ~130 articles with >17,000 citations (h-index=49, Google Scholar), largely in computational MS and bioinformatics.
After her Ph.D. at the University of Padua (Italy), Paola Picotti did postdoctoral research in the group of Ruedi Aebersold at ETH Zurich, where she developed targeted proteomic technologies based on mass spectrometry. In 2011, she was appointed Assistant Professor at the Institute of Biochemistry, ETHZ, and in 2017 tenured Associate Professor at the Institute of Molecular Systems Biology, ETHZ. Major contributions of the Picotti group include the development of structural proteomics technologies to probe in situ protein structural changes, characterization of the determinants of proteome thermostability, large-scale identification of protein-small molecule interactions, and the discovery of regulators of toxic proteins in Parkinson’s disease. Dr. Picotti was awarded the Latsis Prize, the Cotter Award of US HUPO, the SGMS award, the EMBO Young Investigator Award, the Friedrich Miescher Award, the Juan- Pablo Albar award of the European Proteome Association, ERC Starting and Consolidator Grants, and the EMBO Gold Medal.
Nikolai Slavov’s group seeks principles in the coordination among protein synthesis, metabolism, cell growth, and differentiation. The Slavov group has pioneered high-throughput mass-spectrometry methods for quantifying proteins in single cells and is developing new computational methods for analyzing and understanding single-cell proteomics and multimodal data. The group obtained direct evidence for a new regulatory mechanism of protein synthesis (ribosome specialization) and continues to drive research in this emerging field supported by the NIH Director’s New Innovator Award. Dr. Slavov studied biology and physics at MIT before completing a dissertation at Princeton University (Botstein laboratory) with research focused on the coordination among metabolism, growth, and gene expression. He then returned to MIT (van Oudenaarden laboratory) for post-doctoral research that characterized trade-offs of aerobic glycolysis.
Dr. Slavov actively organizes community initiatives, such as the annual single-cell proteomics conference (single-cell.net), which is a highly interactive and interdisciplinary meeting. He also participates and contributes to organizing other leading conferences, including NeurIPS.
Tony is an NHMRC Principal Research Fellow and Deputy Head of Australia’s largest Biochemistry Department at Monash University. He is the Vice President of the Australasian Proteomics Society, a HUPO council member, and also serves as a Scientific Advisory Board Member of the Human Proteome Project.
His laboratory focuses on how the diverse array of peptides presented to the immune system (the immunopeptidome) is influenced by infection, inflammation, and the environment. He has made important contributions to understanding the role of antigen presentation in several autoimmune diseases, drug hypersensitivity, cancer, and infectious diseases. He is well known for work that has highlighted a role for post-translationally modified antigens in immunity. He is one of the most cited Australian proteomics researchers and a leader in the field of immunopeptidomics with over 230 related publications.
Kathryn received her Ph.D. in Biochemistry from the University of Sheffield. After being a laboratory manager for eleven years, she established the Cambridge Centre for Proteomics, University of Cambridge in 2001. She became the Professor in Cellular Dynamics in the Department of Biochemistry University of Cambridge in 2012. She directs a research programme focused on the development and application of technologies to map RNA and protein subcellular localization on a cell-wide scale. Her research looks at the effect of post-transcriptional and post-translational processing on location, and the extent of relocalization in response to cellular stress and disease.
She is a recipient of a Wellcome Trust Investigator Award and a partner in EPIC-XS. She is the recipient of the Juan Pablo Albar Proteome Pioneer Award from the European Proteomics Association for the HUPO Distinguished Achievements in Proteomics award. She was elected as a member of EMBO in July 2020.
Dr. David Fenyö received a Ph.D. in Physics from Uppsala University in Sweden and after switching to computational biology, he did a postdoc at the Rockefeller University, co-founded a bioinformatics company, and worked at GE Healthcare. He has over 30 years of experience with all aspects of biomedical data analysis in both academia and industry and his work has resulted in over 180 scientific publications. In 2010 he joined NYU School of Medicine where he is currently Professor of Biochemistry and Molecular Pharmacology, Director for the Ph.D. program in Systems and Computational Biomedicine, and the Master’s program in Biomedical Informatics. His research focuses on applying data science methods to analyze quantitative data and to model biological systems. His efforts to integrate data from multiple technologies—including mass spectrometry, sequencing, and microscopy—have provided a wide array of powerful tools to discover and verify biomarkers and therapeutic targets in cancer.
Steve Carr is Director of Proteomics at the Broad Institute of MIT and Harvard. Steve and his group collaborate with scientists throughout the Broad Institute community to develop and apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine. Research in his laboratory focuses on developing and applying new computational methods and mass spectrometry (MS)-based technologies to quantify proteins and their modifications and interaction partners in tissues, cells, and biofluids with high sensitivity and specificity; improving informatics for peptide and protein identification by MS and integration of MS-derived data with genomic data to understand disease biology and drug effects. He is Deputy Editor of the journal Molecular and Cellular Proteomics and has >350 publications on the development and application of proteomics and biological MS. Prior to joining the Broad Institute in 2004, he held senior scientific leadership positions at GlaxoSmithKline and at Millennium Pharmaceuticals.
Keep up to date with Official Congress News